HC Wainwright Brokers Increase Earnings Estimates for RYTM

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Rhythm Pharmaceuticals to ($0.72) from a previous estimate of ($0.73), maintaining a "Buy" rating and a $100.00 price target.
• Rhythm Pharmaceuticals' stock has received multiple price target increases from various analysts, with Wells Fargo raising it to $129.00 and Morgan Stanley to $109.00, reflecting strong optimism in the stock's performance.
• The company's latest earnings report showed a larger-than-expected loss of ($0.75) per share, despite a significant year-over-year revenue increase of 66.8%.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Investment analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for shares of Rhythm Pharmaceuticals in a research report issued to clients and investors on Thursday, August 7th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.72) for the quarter, up from their previous estimate of ($0.73). HC Wainwright currently has a "Buy" rating and a $100.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals' Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.86) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.41) EPS.

Several other research analysts have also commented on the company. Wells Fargo & Company lifted their target price on Rhythm Pharmaceuticals from $91.00 to $129.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. Morgan Stanley lifted their target price on Rhythm Pharmaceuticals from $100.00 to $109.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 5th. Oppenheimer lifted their target price on Rhythm Pharmaceuticals from $76.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, July 10th. The Goldman Sachs Group assumed coverage on Rhythm Pharmaceuticals in a research report on Thursday, July 10th. They issued a "buy" rating and a $97.00 target price for the company. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $95.00 target price (up previously from $72.00) on shares of Rhythm Pharmaceuticals in a research report on Wednesday, July 9th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Rhythm Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $101.57.

Rhythm Pharmaceuticals Stock Down 0.5%

RYTM stock opened at $91.98 on Monday. Rhythm Pharmaceuticals has a 52-week low of $43.57 and a 52-week high of $94.80. The stock's 50 day moving average is $75.37 and its two-hundred day moving average is $63.76. The company has a market capitalization of $6.11 billion, a PE ratio of -30.56 and a beta of 2.38.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.09). Rhythm Pharmaceuticals had a negative return on equity of 1,831.43% and a negative net margin of 117.13%. The business had revenue of $48.50 million for the quarter, compared to analysts' expectations of $43.72 million. During the same quarter in the prior year, the firm earned ($0.55) earnings per share. Rhythm Pharmaceuticals's revenue for the quarter was up 66.8% compared to the same quarter last year.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, insider Alastair Garfield sold 1,319 shares of the business's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $64.81, for a total transaction of $85,484.39. Following the completion of the transaction, the insider owned 3,126 shares in the company, valued at $202,596.06. The trade was a 29.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Hunter C. Smith sold 42,120 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $80.48, for a total value of $3,389,817.60. Following the transaction, the chief financial officer owned 116,915 shares of the company's stock, valued at $9,409,319.20. This represents a 26.48% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 81,417 shares of company stock worth $6,352,511. 6.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. boosted its position in Rhythm Pharmaceuticals by 1.0% during the 1st quarter. Victory Capital Management Inc. now owns 17,326 shares of the company's stock worth $918,000 after acquiring an additional 174 shares during the period. Xponance Inc. boosted its position in Rhythm Pharmaceuticals by 4.7% during the 1st quarter. Xponance Inc. now owns 4,365 shares of the company's stock worth $231,000 after acquiring an additional 197 shares during the period. Principal Financial Group Inc. boosted its position in Rhythm Pharmaceuticals by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 37,156 shares of the company's stock worth $1,968,000 after acquiring an additional 272 shares during the period. GF Fund Management CO. LTD. boosted its position in Rhythm Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,573 shares of the company's stock worth $83,000 after acquiring an additional 283 shares during the period. Finally, Two Sigma Advisers LP boosted its position in Rhythm Pharmaceuticals by 2.3% during the 4th quarter. Two Sigma Advisers LP now owns 13,100 shares of the company's stock worth $733,000 after acquiring an additional 300 shares during the period.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.